Cancer pharmacogenomics testing: are we hitting the mark?
The introduction of DPYD testing has launched the NHS into the world of pharmacogenomics, with huge benefits for patients. But with new data showing considerable variation in wait times for test results across England, we look at how this could be improved.
Mclean
Thousands of people with cancer have now been tested to see if they will react negatively to certain types of chemotherapy, in what has become the biggest pharmacogenomics testing scheme in NHS history.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
